Quarterly ResultMay 7, 2026, 08:03 AM
Filana Therapeutics Q1 Net Loss $10.3M; Rebrands, Updates on FDA Hold
AI Summary
Filana Therapeutics reported a significantly reduced net loss of $10.3 million, or $0.21 per share, for Q1 2026, compared to $23.4 million, or $0.48 per share, in Q1 2025. The company also announced its rebranding to Filana Therapeutics, Inc., reflecting its focus on therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy. Filana is actively addressing the FDA's Clinical Hold on simufilam and recently published positive preclinical data supporting its biological rationale.
Key Highlights
- Filana Therapeutics Q1 2026 net loss decreased 56% to $10.3 million from $23.4 million YoY.
- Net loss per share was $0.21, down from $0.48 per share in Q1 2025.
- Cash and cash equivalents were $86.6 million as of March 31, 2026, down from $95.5 million.
- R&D expenses decreased 67% to $4.5 million, primarily due to phasing out the Alzheimer's program.
- G&A expenses decreased 39% to $6.6 million, due to non-recurring legal loss contingencies.
- Company changed its name to Filana Therapeutics, Inc. to reflect focus on filamin A modulation.
- Actively working to address FDA's Clinical Hold for simufilam in TSC-related epilepsy.
- Preclinical data for simufilam published in Epilepsia showed attenuation of seizure progression.